Autolus Therapeutics plc
AUTL · Biological Products, (No Diagnostic Substances) · 266.2M shares · +88%/yr ↑ dilution · EDGAR filings ↗
Grade
D44Clinical/early-stage biotech — early-commercial CAR-T (Aucatzyl/obe-cel), heavy burn ($303M), funded.
Strengths
- Liquidity — current ratio 5.9 (60th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- No interest coverageInterest coverage -7.38 (cannot cover interest)
- Auditor changeRecent 8-K item 4.01 8-K ↗
- Net lossNet loss (net margin -381.4%)
- Cash burnNegative free cash flow (-302.6M)
- Chronic dilutionShare count +88%/yr over 2y (dilution, book value/share -55%)
- Notable holderHeld by 4 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
-27.8%
Operating margin
-358.9%
Net margin
-381.4%
Return on equity
-161.4%
Return on assets
-48.8%
Revenue growth (QoQ)
7.9%
Interest coverage
-7.4×
Current ratio
5.9×
Free cash flow
-$303M
EBITDA
-$262M
Tangible book value
$158M
Cash & investments
$301M
Cash runway
4q
Stock comp / revenue
19.2%
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-09 | 2026-06-05 | 0001730463-26-000069 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001730463-26-000058 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001730463-26-000065 ↗ |
| 8-K | 2026-04-29 | 2026-04-29 | 0001193125-26-192362 ↗ |
| 8-K | 2026-04-16 | 2026-04-14 | 0001730463-26-000049 ↗ |
| 8-K | 2026-04-08 | 2026-04-08 | 0001730463-26-000043 ↗ |
| 10-K | 2026-03-27 | 2025-12-31 | 0001730463-26-000038 ↗ |
| 8-K | 2026-03-27 | 2026-03-27 | 0001730463-26-000032 ↗ |
| 8-K | 2026-01-26 | 2026-01-21 | 0001730463-26-000019 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001730463-26-000012 ↗ |
| 8-K | 2025-12-02 | 2025-12-01 | 0001730463-25-000095 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001730463-25-000088 ↗ |